SCHEMBL430891

SCHEMBL430891

COc1cccc(-c2cc(NCc3ccc4c(c3)OCO4)nc(N)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR Q13258 2/20 0.56
CLK4 Q9HAZ1 3/20 0.55
BRAF P15056 1/20 0.50
ALDH1A1 P00352 3/20 0.49
DYRK1A Q13627 1/20 0.48
PTGS2 P35354 1/20 0.48
ADORA3 P0DMS8 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA1 P30542 1/20 0.47
PDE5A O76074 1/20 0.47
MAPK1 P28482 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
TSHR P16473 2/20 0.47
CYP2C19 P33261 2/20 0.47
TP53 P04637 2/20 0.47
HIF1A Q16665 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29379328 1.00 PTGDR (0.56) PTGDRCLK4BRAFALDH1A1DYRK1A
Hydrochloric Acid SCHEMBL29549744 0.99 PTGDR (0.55) PTGDRCLK4BRAFALDH1A1DYRK1A
Hydrochloric Acid SCHEMBL19668265 0.99 PTGDR (0.55) PTGDRCLK4BRAFALDH1A1DYRK1A
SCHEMBL24454337 0.91 DYRK1A (0.51) PTGDRCLK4ALDH1A1DYRK1APDE5A
SCHEMBL22541070 0.90 ALDH1A1 (0.49) PTGDRCLK4BRAFALDH1A1DYRK1A
SCHEMBL24454264 0.90 CLK4 (0.47) PTGDRCLK4BRAFALDH1A1DYRK1A
SCHEMBL24454573 0.90 BRAF (0.48) PTGDRCLK4BRAFALDH1A1DYRK1A
SCHEMBL22541055 0.90 BRAF (0.46) PTGDRCLK4BRAFALDH1A1DYRK1A
SCHEMBL22541061 0.89 CLK4 (0.46) PTGDRCLK4BRAFALDH1A1DYRK1A
SCHEMBL22533936 0.87 CALM1 (0.51) CLK4ALDH1A1DYRK1APDE5AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154468-A1 METHOD FOR INDUCING DEDIFFERENTIATION OF ADIPOCYTES CITY UNIVERSITY OF HONG KONG (HK) 2025-05-15 US claimed
US-20240240154-A1 COLONIC ORGANOIDS AND METHODS OF MAKING AND USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-07-18 US claimed
CN-118355110-A Method for producing cartilage and bone 默多克儿童研究所 2024-07-16 CN claimed
US-20240166998-A1 METHOD FOR PRODUCING HEMATOPOIETIC CELLS FROM STEM CELLS USING VASCULAR ORGANOIDS GALAT, Yekaterina 2024-05-23 US claimed
EP-4326852-A1 METHOD FOR PRODUCING HEMATOPOIETIC CELLS FROM STEM CELLS USING VASCULAR ORGANOIDS Artec Biotech, Inc. (US) 2024-02-28 EP claimed
US-11767515-B2 Colonic organoids and methods of making and using same CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-09-26 US claimed
EP-3914697-A1 CHOROID PLEXUS ORGANOIDS AND METHODS FOR PRODUCTION THEREOF United Kingdom Research and Innovation (GB) 2021-12-01 EP claimed
CN-113631701-A Choroid plexus organoids and methods of producing the same 英国研究与创新组织 2021-11-09 CN claimed
US-20210324334-A1 ORGANOID COMPOSITIONS FOR THE PRODUCTION OF HEMATOPOIETIC STEM CELLS AND DERIVATIVES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER 2021-10-21 US claimed
EP-3856765-A1 STEM CELL-DERIVED HUMAN MICROGLIAL CELLS, METHODS OF MAKING AND METHODS OF USE Memorial Sloan Kettering Cancer Center (US) 2021-08-04 EP claimed
EP-2788472-A2 METHOD OF DIRECTED DIFFERENTIATION PRODUCING CORNEAL ENDOTHELIAL CELLS, COMPOSITIONS THEREOF, AND USES THEREOF Advanced Cell Technology, Inc. (US) 2014-10-15 EP claimed
WO-2014143022-A1 COMPOSITIONS AND METHODS FOR TREATING RETINAL DISEASE TRESE MICHAEL T (US) 2014-09-18 WO claimed
US-20140199277-A1 Methods of Treatment of Retinal Degeneration Diseases Sanges, Daniela (ES) 2014-07-17 US claimed
EP-2739723-A1 METHODS OF TREATMENT OF RETINAL DEGENERATION DISEASES Cosma, Maria Pia (ES) 2014-06-11 EP claimed
WO-2014018691-A1 GENERATION OF AIRWAY AND LUNG PROGENITORS AND EPITHELIAL CELLS AND THREE-DIMENSIONAL ANTERIOR FOREGUT SPHERES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-01-30 WO claimed
WO-2013086236-A2 METHOD OF DIRECTED DIFFERENTIATION PRODUCING CORNEAL ENDOTHELIAL CELLS, COMPOSITIONS THEREOF, AND USES THEREOF ADVANCED CELL TECHNOLOGY, INC. (US) 2013-06-13 WO claimed
WO-2013020945-A9 METHODS OF TREATMENT OF RETINAL DEGENERATION DISEASES COSMA MARIA PIA (ES) 2013-04-04 WO claimed
WO-2013020945-A1 METHODS OF TREATMENT OF RETINAL DEGENERATION DISEASES COSMA MARIA PIA (ES) 2013-02-14 WO claimed
WO-2011049954-A2 COMPOSITIONS COMPRISING WNT MODULATORS OR NEUROTOXINS FOR THE TREATMENT OF OTIC DISORDERS OTONOMY, INC. (US) 2011-04-28 WO claimed
WO-2008133904-A1 METHODS AND COMPOSITIONS FOR STEM CELL SELF-RENEWAL STOWERS INSTITUTE FOR MEDICAL RESEARCH (US) 2008-11-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140199277-A1 Methods of Treatment of Retinal Degeneration Diseases ALDH1A2, NR2E3, RARB PTGDR 2485/4885CLK4 3354/4885BRAF 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.